ClinicalTrials.gg
CompletedNCT00234104Updated Dec 25, 2013Results posted

A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)

A Phase 2 interventional study of OPC-41061(Tolvaptan) in Heart Failure, Congestive and Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-12-25.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
7th of 19
122 · median 60
Started
2004
with 1 other
Phase 2
4 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
3 of 19
Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 7th largest by enrollment, is one of 2 that started in 2004, is one of 4 in phase 2, and was the 6th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

This drug is being developed to treat cardiac edema. The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in patients with extracellular volume expansion secondary to CHF despite taking furosemide at 40 mg/d or more. This study is being conducted in Japan.

03

Conditions studied

  • Heart Failure, Congestive
  • Edema

Keywords

  • OPC-41061
  • Tolvaptan
  • Heart Failure
  • Edema
  • Extracellular volume expansion
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, pulmonary congestion, or 3rd sound due to extracellular volume expansion
  2. Hospitalized patients or patients who can be hospitalized for the study from the commencement of the observation period to the end-of-study examination
  3. Men and women between the ages of 20 and 80 (non-inclusive) at the time of giving consent
  4. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period
  5. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration

Exclusion criteria

Exclusion Criteria:

  1. Patients with unstable heart failure (acute heart failure, acute exacerbation of chronic heart failure, etc)
  2. Patients with an implanted ventricular assist device
  3. Patients who have undergone or are scheduled to undergo any of the following procedures

    • Heart surgery involving thoracotomy within 60 days prior to the screening examination
    • Pacemaker implant surgery involving bilateral pacing within 60 days prior to the screening examination
    • Angioplasty, electrophysiologic device implantation, ventricular assist device implantation, heart transplant, or other cardiac surgery scheduled within 30 days after the screening examination
  4. Patients with any of the following diseases, complications, or symptoms

    • Suspected hypovolemia
    • Onset of acute myocardial infarction within 30 days prior to the screening examination
    • Hypertrophic cardiomyopathy (excluding diastolic phase)
    • Definitively diagnosed active myocarditis or amyloid cardiomyopathy
    • Valvular heart disease with significant stenosis
    • Untreated thyroid disease
    • Progressive neurological disease (Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc) or severe episodic neurological disease (epilepsy, Guillain-Barre syndrome, etc)
    • Diabetes with poor glycemic control
    • Anuria
    • Hepatic coma
    • Hyponatremia of moderate or greater severity (serum Na \< 120 mEq/L)
  5. Patients with a history of the following conditions

    • Occurrence of sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination (except for patients using an implantable cardioverter-defibrillator)
    • Evident cerebral infarction
    • Multiple stroke
    • Occurrence of a cerebrovascular accident within 30 days prior to the screening examination
    • or idiosyncratic reaction to benzazepine derivatives, such as benazapril
  6. Patients with a history of drug abuse or alcoholism in the past year
  7. Patients in a state of morbid obesity with a (weight[kg] ÷ height [m]2) over 35
  8. Patients with a supine systolic arterial blood pressure of less than 90 mmHg
  9. Patients with any of the following abnormal laboratory values: \<9 g/dL, total >3.0 mg/dL, serum creatine >3.0 mg/dL, serum Na >147 mEq/L, or serum K >5.5 mEq/L
  10. Patients not capable of taking oral medication
  11. Patients who are nursing, pregnant, capable of pregnancy, or intending to become pregnant during or shortly after the study period
  12. Patients who have taken a study drug other than OPC-41061 within 30 days prior to screening
  13. Patients who have previously taken OPC-41061 in this study or another study of OPC-41061
  14. Patients otherwise judged by the principal investigator or attending investigator to be inappropriate for inclusion in the study (eg, patients with hepatic cirrhosis, renal disease, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
122 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Body Weight

    The body weight change from baseline following final trial drug administration

    Time frame: Baseline, at the time of final trial drug administration

07

Results

Posted Dec 25, 2013

Participant flow

Participant flow — Overall Study
MilestonePlacebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061
Started30293429
Completed26282921
Not completed4158
Withdrew: Adverse event4035
Withdrew: Protocol violation0001
Withdrew: Physician decision0122

Outcome measures

PrimaryBody Weight

The body weight change from baseline following final trial drug administration

Time frame:
Baseline, at the time of final trial drug administration
Reported as:
Mean · Kg
Body Weight
KgPlacebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061
Body Weight-0.53 ± 0.96-1.62 ± 1.55-1.35 ± 1.54-1.85 ± 1.10
Statistical analysis
  • Placebo vs 15 mg of OPC-41061 · t-test, 2 sided · p = 0.0074 · Mean difference (final values): -1.09Dunnett's test was used
  • Placebo vs 30 mg of OPC-41061 · t-test, 2 sided · p = 0.0459 · Mean difference (final values): -0.82Dunnett's test was used
  • Placebo vs 45 mg of OPC-41061 · t-test, 2 sided · p = 0.0010 · Mean difference (final values): -1.32Dunnett's test was used

Adverse events

Collected over 7 days. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/29 (13.8%)14/29 (48.3%)
15 mg of OPC-41061—0/28 (0%)21/28 (75%)
30 mg of OPC-41061—1/33 (3%)25/33 (75.8%)
45 mg of OPC-41061—2/28 (7.1%)21/28 (75%)
Most frequent serious events
Most frequent serious events
EventPlacebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061
Transient Ischaemic AttackNervous system disorders0/290/280/331/28
Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders0/290/280/331/28
Cardiac Failure CongestiveCardiac disorders1/290/280/330/28
Cardio-Respiratory ArrestCardiac disorders1/290/280/330/28
Umbilical HerniaGastrointestinal disorders1/290/280/330/28
Sudden DeathGeneral disorders1/290/280/330/28
EpistaxisRespiratory, thoracic and mediastinal disorders0/290/281/330/28
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlacebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061
ThirstGeneral disorders3/296/289/3315/28
Blood Uric Acid IncreasedInvestigations0/296/284/332/28
DehydrationMetabolism and nutrition disorders2/290/283/336/28
ConstipationGastrointestinal disorders3/291/286/331/28
Blood Urea IncreasedInvestigations1/293/282/332/28
DizzinessNervous system disorders0/293/281/332/28
HeadacheNervous system disorders0/293/280/330/28
Protein Urine PresentInvestigations3/290/281/330/28
DiarrhoeaGastrointestinal disorders0/291/283/331/28
Cardiac Failure CongestiveCardiac disorders0/290/281/332/28

Baseline characteristics

1 Subject of each arm were excluded form the analysis set because emergency codes were lost.

Age, Categorical
Age, Categorical(Participants)Placebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061Total
<=18 years00000
Between 18 and 65 years1110111446
>=65 years1818221472
Age Continuous
Age Continuous(years)Placebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061Total
Mean67.9 ± 9.466.9 ± 9.666.4 ± 12.562.6 ± 12.566.0 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061Total
Female11138436
Male1815252482
Region of Enrollment
Region of Enrollment(participants)Placebo15 mg of OPC-4106130 mg of OPC-4106145 mg of OPC-41061Total
Japan29283328118
08

Study locations

1 site
  • Otsuka Pharmaceutical Co., Ltd.
    Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 7 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2005
First posted
Oct 6, 2005
Start
Aug 2004
Primary completionActual
Jan 2006
CompletionActual
Jan 2006
Results first posted
Dec 25, 2013
Last update
Dec 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00234104
Responsible party
Sponsor
First posted
Oct 6, 2005
Start date
Aug 2004
Primary completion
Jan 2006
Completion
Jan 2006
Results posted
Dec 25, 2013
Last update
Dec 25, 2013

Study contacts

Katsuhisa Saito
study director · Division of New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion